SLT Contact Laser promotional violations result in FDA warning letter.
This article was originally published in The Gray Sheet
SLT CONTACT LASER PROMOTION FOR UNAPPROVED UROLOGICAL INDICATIONS renders the device adulterated and misbranded, FDA says in a Dec. 28 warning letter to the company. Promotional statements such as those claiming that use of Surgical Laser Technologies' Nd:YAG contact laser is superior to transurethral resection of the prostate "have not been substantiated to the agency" and must receive premarket clearance, FDA says.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.